New Formulation of Tesamorelin Available for HIV Patients With Lipodystrophy

Theratechnologies announced the availability of Egrifta SV, a new single-vial formulation of tesamorelin for injection.

Egrifta SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is supplied as a lyophilized powder in a 2mg single-dose vial with diluent and can be stored at room temperature. The more concentrated formulation allows for a smaller volume of administration (0.35mL).

Egrifta SV and the original version, Egrifta, have differences in the dosage, the number of vials required to prepare a dose, reconstitution instructions, and storage requirements. With Egrifta, 2 vials of 1mg must be reconstituted with the diluent provided.

“Given its many improvements over the original version of tesamorelin, Egrifta SV should help sustain growth for tesamorelin over the coming years. We are committed to continue managing the lifecycle of our products in order to help people living with HIV,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.

For more information visit egriftasv.com.

The post New Formulation of Tesamorelin Available for HIV Patients With Lipodystrophy appeared first on Infectious Disease Advisor.

Theratechnologies announced the availability of Egrifta SV, a new single-vial formulation of tesamorelin for injection.

The post New Formulation of Tesamorelin Available for HIV Patients With Lipodystrophy appeared first on Infectious Disease Advisor.